摘要
为增强导向治疗的“弹头”杀伤力，提高肝癌导向综合治疗的疗效，对马抗人ＡＦＰ抗体进行了１３１Ⅰ和丝裂霉素（ＭＭＣ）双标记，制备同时携带１３１Ⅰ和ＭＭＣ的“双弹头”马抗人ＡＦＰ抗体（１３１Ⅰ－ＡＦＰＡｂ－ＭＭＣ）。荷人肝癌裸鼠的定位显像和抑癌率实验显示１３１Ⅰ－ＡＦＰＡｂ－ＭＭＣ具有良好的定位显像作用，抑癌率达７３．５％，明显高于对照组（Ｐ＜０．０５）。２２例配对的中晚期原发性肝癌患者的“双弹头”导向综合治疗结果：治疗组的有效率（ＣＲ＋ＰＲ＋ＭＲ）为６３．２％明显高于对照组（３１．８％），Ｐ＜０．０５；治疗组的１年生存率（５２．６％）亦明显高于对照组（２２．７％）Ｐ＜０．０５，且无严重毒副作用。表明：１３１Ⅰ－ＡＦＰＡｂ－ＭＭＣ的“双弹头”
The 'Double Warhead' immunoconjugate ( 131 I AFPAb MCC) was prepared by labelling 131 I and Mitomycin c (MMC) to equine anti AFP antibody following the technic of directly cojugated and modified chloramin T method. In nude mice bearing human HCC, the 131 I AFPAb MMC was found localized well in tumor tissues and the inhibitory effect was stronger than 'Single Warhead' or 'Single antibody' ( P <0.05).Twenty two randomized patients with advanced HCC have been treated by multimodality treatment using 'Double Warhead'. The rates of tumor shrinkage and one year survival in this series were 68.4% (13/19) and 52.6% (10/19) which were higher than those in the control group 40.9% (9/22) and 22.7% (5/22) respectively.The results indicated that 'Doubl e Warhead' targeting treatment might raise the therapeutic effect of moderate or advanced stage HCC.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1998年第1期44-46,共3页
Chinese Journal of Clinical Oncology
基金
"八五"国家攻关计划基金
关键词
导向治疗
抗体
肝肿瘤
AFP
综合疗法
Hepatocellular carcinoma Antibody 131 I Radioimmunotherapy
